e18190 Background: Upper extremity deep venous thrombosis (UE DVT) is a known complication in patients with cancer. However, the cumulative incidence by cancer type, risk factors associated with UE DVT and impact on survival is not well-described. Methods: Using the California Cancer Registry , we identified patients with 10 common malignancies (2005-2014) and linked this to the California hospitalization and emergency department databases to find patients with an incident UE DVT event using specific ICD-9-CM codes. We determined cumulative incidence of UE DVT adjusted for the competing risk of death. Using Cox proportional hazards regression, stratified by tumor type and adjusted for other prognostic covariates including central venous catheters (CVC), we identified risk factors for developing UE DVT and the impact of UE DVT on overall survival. Patients with venous thromboembolism prior to malignancy diagnosis were excluded. Results: Among 785,444 patients with malignancy, 6,099 (0.8%) had an incident UE DVT. The 24-month cumulative incidence of UE DVT varied by cancer type (Table). Most UE DVT (62.2%) occurred in patients with CVC. VTE after cancer diagnosis and CVC substantially increased the risk for UE DVT across all cancers. UE DVT was also associated with worse overall survival for all malignancies with hazard ratios ranging from 1.52 to 3.72. Conclusions: UE DVT is a rare but important complication among patients with malignancy, with incidence highest in leukemia and lowest in prostate cancer. Although uncommon, UE DVT may affect prognosis in patients with malignancy as it is associated with an increased hazard of death. Table: 24-month cumulative incidence of UE DVT, adjusted for the competing risk of death, in 10 common malignancies among California cancer patients, 2005-2014. [Table: see text]
Upper extremity deep venous thrombosis: risk factors, diagnosis, treatment
